-
公开(公告)号:US20190240292A1
公开(公告)日:2019-08-08
申请号:US16360838
申请日:2019-03-21
发明人: George Tidmarsh , Lakhmir Chawla
CPC分类号: A61K38/22 , A61K9/0019 , A61K38/08 , A61K38/10 , A61K38/1709 , A61K45/06 , Y02A50/385 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/473
摘要: The present disclosure relates to the use of hepcidin in therapeutic methods for the treatment of various conditions in which decreasing serum iron concentration may be beneficial.
-
公开(公告)号:US20190231850A1
公开(公告)日:2019-08-01
申请号:US16255105
申请日:2019-01-23
摘要: Pharmaceutical compositions comprising PYY (e.g., PYY(3-36) and analogs and variants thereof), satiety peptides, satiety hormones, metabolic hormones, and methods of treating metabolic diseases with such compositions are provided. Aspects include methods of increasing a feeling of fullness in patients treated with pharmaceutical compositions comprising PYY, PYY(3-36), satiety peptides, satiety hormones, metabolic hormones, and analogs, receptor antagonists and variants thereof.
-
公开(公告)号:US20190216900A1
公开(公告)日:2019-07-18
申请号:US16143735
申请日:2018-09-27
发明人: Vishal Bansal
摘要: The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject, comprising administering to the subject an effective amount of a compound comprising ghrelin.
-
公开(公告)号:US20190002513A1
公开(公告)日:2019-01-03
申请号:US16034654
申请日:2018-07-13
发明人: Jeffrey Schlom , Kwong-Yok Tsang
IPC分类号: C07K14/47 , C12N7/00 , A61K38/19 , A61K38/20 , A61K38/22 , A61K31/00 , C07K14/82 , A61K45/06 , A61K39/39 , A61K39/00 , A61K38/21 , A61K38/00
CPC分类号: C07K14/4727 , A61K31/00 , A61K38/00 , A61K38/191 , A61K38/193 , A61K38/195 , A61K38/20 , A61K38/217 , A61K38/22 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/5154 , A61K2039/53 , A61K2039/55588 , C07K14/82 , C07K2319/00 , C12N7/00 , C12N2710/24143 , C12N2710/24171 , A61K2300/00
摘要: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
-
公开(公告)号:US10076507B1
公开(公告)日:2018-09-18
申请号:US15817057
申请日:2017-11-17
IPC分类号: A61K31/198 , A61K31/426 , A61K36/87 , A61K31/05 , A61K31/191 , A61K31/216 , A61K31/015 , A61K31/353 , A61K31/336 , A61K31/366 , A61K31/155 , A23L33/175 , A61K45/06 , A23L2/52 , A61K31/194 , A61K31/192 , A61K31/4439 , A61K38/22 , A61K31/522 , A61K31/19 , A23L33/00
CPC分类号: A61K31/198 , A23L2/52 , A23L33/175 , A23L33/30 , A23V2002/00 , A61K31/015 , A61K31/05 , A61K31/155 , A61K31/19 , A61K31/191 , A61K31/192 , A61K31/194 , A61K31/216 , A61K31/336 , A61K31/353 , A61K31/366 , A61K31/426 , A61K31/4439 , A61K31/522 , A61K36/87 , A61K38/22 , A61K45/06 , A61K2300/00
摘要: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.
-
公开(公告)号:US10071165B2
公开(公告)日:2018-09-11
申请号:US14898209
申请日:2014-05-29
发明人: Changqing Xia , Yixian Guo , Haitao Wu , Suigui Wan
IPC分类号: A61K39/385 , A61K39/00 , A61K47/48 , A61K38/18 , A61K38/22 , A61K35/17 , A61K47/62 , A61K47/69
CPC分类号: A61K47/64 , A61K35/17 , A61K38/18 , A61K38/22 , A61K39/0011 , A61K39/385 , A61K47/62 , A61K47/646 , A61K47/6901 , A61K2039/5156 , A61K2039/54 , A61K2039/55566 , A61K2039/575 , A61K2039/6006 , A61K2039/62 , A61K2039/627
摘要: The present invention pertains to immunology, biomedicine field, specifically relates to a protein-cell conjugate, which is characterized in that the protein and the cell are coupled via a bifunctional cross-linking agent. The present invention further relates to a preparation method and uses of the protein-cell conjugate. The protein-cell conjugate of the present invention can be used for prevention or treatment of many diseases, such as malignant tumors, infectious diseases and autoimmune diseases.
-
公开(公告)号:US20180243338A1
公开(公告)日:2018-08-30
申请号:US15558999
申请日:2016-03-18
发明人: Akihiko TAGUCHI , Kenichi YAMAHARA , Yukiko NIINO
CPC分类号: A61K35/14 , A61K35/28 , A61K38/1709 , A61K38/1825 , A61K38/1841 , A61K38/1858 , A61K38/1866 , A61K38/22 , A61K38/46 , A61K38/48 , A61K38/4886 , A61K45/00 , A61P9/10 , A61P13/12 , C12N5/0087 , C12Y304/24024
摘要: The present invention provides a sufficiently effective medicine for treatment and/or prevention of ischemic diseases, without performing isolation of therapeutic cells or removal of deleterious cells from blood cells/hemocytes. The blood cells and/or the hemocytes are subjected to the action of a saccharide. The saccharide is a monosaccharide, a disaccharide, a trisaccharide, a polysaccharides, or a copolymer containing a monosaccharide, a disaccharide, or a trisaccharide as a component. The saccharide is a copolymer of sucrose and epichlorohydrin.
-
公开(公告)号:US10034944B2
公开(公告)日:2018-07-31
申请号:US15604935
申请日:2017-05-25
IPC分类号: A61K47/24 , A61K33/00 , A61K9/107 , A61K38/06 , A61K9/00 , A61K38/22 , A61K9/06 , A61K45/06 , A61K38/09
CPC分类号: A61K47/24 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K33/00 , A61K38/066 , A61K38/09 , A61K38/22 , A61K45/06 , A61K2300/00
摘要: The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and/or promoting wound healing. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
-
公开(公告)号:US20180207234A1
公开(公告)日:2018-07-26
申请号:US15863386
申请日:2018-01-05
IPC分类号: A61K38/17 , A61K31/713 , A61K38/22 , A61K38/43 , G01N33/574 , C07K16/18 , G01N33/68 , A61K31/7105 , A61K39/00
CPC分类号: A61K38/1709 , A61K31/7105 , A61K31/713 , A61K38/22 , A61K38/43 , A61K39/00 , A61K2039/505 , C07K16/18 , C07K2317/34 , C07K2317/76 , G01N33/5743 , G01N33/57496 , G01N33/6875 , G01N2333/4703 , G01N2500/00 , G01N2500/04 , G01N2500/10
摘要: The present invention relates to methods for treating or preventing cancer and metastasis. More particularly, the present invention relates to methods for treating or preventing cancer by decreasing the expression and/or activity of Flightless I. Also provided are methods for inhibiting the growth of a cancerous cell and methods for inhibiting formation and/or growth of a tumour which also rely on decreasing the expression and/or activity of Flightless I. The present invention also extends to methods for diagnosing cancer, methods for determining if a subject is susceptible to developing cancer, and methods for assessing progression of cancer based on the finding that increased expression and/or activity of Flightless I is associated with cancer development, growth and metastasis. The present invention also provides methods for screening for a candidate therapeutic agent useful for treating or preventing cancer, and related pharmaceutical compositions and kits.
-
公开(公告)号:US20180161390A1
公开(公告)日:2018-06-14
申请号:US15571039
申请日:2016-04-29
发明人: Henry HSU
CPC分类号: A61K38/08 , A61K9/0048 , A61K31/4725 , A61K38/00 , A61K38/13 , A61K38/22 , A61K45/06 , A61P27/02 , C07K7/06 , C07K14/47 , C07K14/5759 , A61K2300/00
摘要: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
-
-
-
-
-
-
-
-
-